Young Research & Publishing Inc.

Investment Research Since 1978

Compensation was paid to utilize rankings. Click here to read full disclosure.

  • About Us
    • Contributors
    • Archives
    • Dick Young’s Safe America
    • The Final Richard C. Young’s Intelligence Report
    • You’ve Read The Last Issue of Intelligence Report, Now What?
    • Dick Young’s Research Key: Anecdotal Evidence Gathering
    • Crisis at Vanguard
  • Investment Analysis
    • Bonds
    • Currencies and Gold
    • Dividend Investing
    • ETFs & Funds
    • Investment Strategy
    • Retirement Investing
    • Stocks
    • The Efficient Frontier
  • Investment Counsel
  • Retirement Compounders®
  • Free Email Signup

FOMO a Dangerous Investment Strategy

July 13, 2018 By Jeremy Jones, CFA

By chartcameraman @ Shutterstock.com

In a market where a narrow band of equities is producing the lion’s share of gains, it can be tempting for fund managers to chase those stocks because of their fear of missing out, or FOMO. That FOMO can cause managers to do things they wouldn’t normally. Charley Grant discusses some of this activity in the market at The Wall Street Journal. He writes:

Fear of being left behind is a powerful force among fund managers, even if it means taking big risks.

This year, managers not invested in tech stocks should be polishing their résumés. In the first six months of the year, technology shares accounted for more than 100% of the gains in the S&P 500.

Stocks in other sectors where investors see growth prospects can rise sharply too—as long as they have a story to tell Wall Street. Pepsi shares had their best day in nearly a decade on Tuesday after an earnings report showed its North American beverage sales had mostly stopped falling.

The best recent example of this phenomenon is Biogen , whose shares soared by about 20% last Friday, adding about $13 billion to the company’s market value. That move came after the biotech giant and its Japanese partner Eisai announced promising clinical data for patients with Alzheimer’s disease. All of a sudden, what had been a value stock became a compelling growth story, and Wall Street didn’t want to be left behind.

The stock has mostly held those gains, even as some analysts expressed skepticism that the full data will pass muster when Biogen eventually shows it. History is on the skeptics’ side; the historical success rate for clinical trials in Alzheimer’s disease is below 1%. For now, however, that is a risk that shareholders are mostly willing to accept.

Read more here.

Share this:

  • Email
  • Twitter
  • Facebook

You Might Also Like:

  • Steam Rolled
  • A 2019 Survival Guy Investment Strategy
  • Your Retirement Life: Investment Planning in One Chart
  • Author
  • Recent Posts
Jeremy Jones, CFA
Jeremy Jones, CFA, CFP® is the Director of Research at Young Research & Publishing Inc., and the Chief Investment Officer at Richard C. Young & Co., Ltd. CNBC has ranked Richard C. Young & Co., Ltd. as one of the Top 100 Financial Advisors in the nation (2019-2022) Disclosure. Jeremy is also a contributing editor of youngresearch.com.
Latest posts by Jeremy Jones, CFA (see all)
  • Money Market Assets Hit Record High: $5.4 Trillion - May 26, 2023
  • The Mania in AI Stocks Has Arrived - May 25, 2023
  • The Wisdom of Sam Zell - May 24, 2023

Search Young Research

Most Popular

  • Wellington and Wellesley Funds Not Managed by Vanguard
  • The Single Worst Market Timing Event in History
  • “No Way I’m Spending That Much on Those”
  • The Power of a Compound Interest Table
  • Should America Move Closer to the Saudis, or Push them Away?
  • The War Machine's Manpower Problem
  • Will the Fed Hold Up Its End of the Bargain?
  • Vanguard Wellesley (VWINX) vs. Wellington (VWELX): Which Fund is Best?
  • “You Didn’t Eat That Again, Did You?”
  • Mr. Protect and Preserve: For Where We’re Going

Don’t Miss

Default Risk Among the Many Concerns with Annuities

Risk and Reward: An Efficient Frontier

How to be a Billionaire: Proven Strategies from the Titans of Wealth

Cryptocosm and Life After Google

Warning: Avoid Mutual Fund Year End Distributions

Is Gold a Good Long-term Investment?

How to Invest in Gold

Vanguard Wellington (VWELX): The Original Balanced Fund

What is the Best Gold ETF for Investing and Trading?

Procter & Gamble (PG) Stock: The Only True Dividend King

The Dividend King of the North

You’ll Love This if You’re Dreaming of an Active Retirement Life

The Importance of a Balanced Portfolio

Invest with Peace of Mind and Comfort

What Kind of Life Are You Investing For?

RSS The Latest at Richardcyoung.com

  • The Elephant in the Room
  • “Then One Day the Grandfather was Gone”
  • My Key West Garden Office
  • Does a New Antiviral Covid Drug Do More Harm than Good?
  • The Biden Regime Treats Americans Worse than Illegal Immigrants
  • Key West #1 Wine Shop & Wine Expert
  • California – First to Enact Statewide Gun and Ammo Tax
  • “No Way I’m Spending That Much on Those”
  • How Much Can Grid Battery Storage Help?
  • Fighting Russian Power with a Hill of Crosses

RSS The Latest at Yoursurvivalguy.com

  • “Then One Day the Grandfather was Gone”
  • “No Way I’m Spending That Much on Those”
  • What Trade Policy Serves America’s National Interest Best?
  • California Wants to Make the 2nd Amendment Unaffordable
  • “You Didn’t Eat That Again, Did You?”
  • Is McCarthy Up to the Task?
  • Rising Costs Are Hammering Commercial Real Estate
  • Your Survival Guy Fishing with Dolphins
  • Judge Shatters California High Capacity Magazine Ban
  • Is Your Water Safe to Drink? NOLA Residents Aren’t Sure

About Us

  • About Young Research
  • Archives
  • Contributors

Our Partners

  • Richard C. Young & Co.
  • Richardcyoung.com

Copyright © 2023 | Terms & Conditions

 

Loading Comments...
 

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.